AbbVie to Acquire Apogee Therapeutics for 10.9 Billion

AbbVie has agreed to purchase biotech firm Apogee Therapeutics in a cash deal valued at 10.9 billion dollars. The acquisition is intended to strengthen the company's immunology pipeline with next-generation treatments.